458 related articles for article (PubMed ID: 26092726)
1. A Key Role for Leukemia Inhibitory Factor in C26 Cancer Cachexia.
Seto DN; Kandarian SC; Jackman RW
J Biol Chem; 2015 Aug; 290(32):19976-86. PubMed ID: 26092726
[TBL] [Abstract][Full Text] [Related]
2. Cryptotanshinone prevents muscle wasting in CT26-induced cancer cachexia through inhibiting STAT3 signaling pathway.
Chen L; Yang Q; Zhang H; Wan L; Xin B; Cao Y; Zhang J; Guo C
J Ethnopharmacol; 2020 Oct; 260():113066. PubMed ID: 32505837
[TBL] [Abstract][Full Text] [Related]
3. Myostatin is a novel tumoral factor that induces cancer cachexia.
Lokireddy S; Wijesoma IW; Bonala S; Wei M; Sze SK; McFarlane C; Kambadur R; Sharma M
Biochem J; 2012 Aug; 446(1):23-36. PubMed ID: 22621320
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia.
Silva KA; Dong J; Dong Y; Dong Y; Schor N; Tweardy DJ; Zhang L; Mitch WE
J Biol Chem; 2015 Apr; 290(17):11177-87. PubMed ID: 25787076
[TBL] [Abstract][Full Text] [Related]
5. Tumour-derived leukaemia inhibitory factor is a major driver of cancer cachexia and morbidity in C26 tumour-bearing mice.
Kandarian SC; Nosacka RL; Delitto AE; Judge AR; Judge SM; Ganey JD; Moreira JD; Jackman RW
J Cachexia Sarcopenia Muscle; 2018 Dec; 9(6):1109-1120. PubMed ID: 30270531
[TBL] [Abstract][Full Text] [Related]
6. IL-17A contributes to skeletal muscle atrophy in lung cancer-induced cachexia via JAK2/STAT3 pathway.
Ying L; Yao Y; Lv H; Lu G; Zhang Q; Yang Y; Zhou J
Am J Physiol Cell Physiol; 2022 May; 322(5):C814-C824. PubMed ID: 35319902
[TBL] [Abstract][Full Text] [Related]
7. Valproic acid attenuates skeletal muscle wasting by inhibiting C/EBPβ-regulated atrogin1 expression in cancer cachexia.
Sun R; Zhang S; Hu W; Lu X; Lou N; Yang Z; Chen S; Zhang X; Yang H
Am J Physiol Cell Physiol; 2016 Jul; 311(1):C101-15. PubMed ID: 27122162
[TBL] [Abstract][Full Text] [Related]
8. Pantoprazole blocks the JAK2/STAT3 pathway to alleviate skeletal muscle wasting in cancer cachexia by inhibiting inflammatory response.
Guo D; Wang C; Wang Q; Qiao Z; Tang H
Oncotarget; 2017 Jun; 8(24):39640-39648. PubMed ID: 28489606
[TBL] [Abstract][Full Text] [Related]
9. Alantolactone ameliorates cancer cachexia-associated muscle atrophy mainly by inhibiting the STAT3 signaling pathway.
Shen Q; Kuang JX; Miao CX; Zhang WL; Li YW; Zhang XW; Liu X
Phytomedicine; 2022 Jan; 95():153858. PubMed ID: 34861585
[TBL] [Abstract][Full Text] [Related]
10. Stimulation of the JAK/STAT pathway by LIF and OSM in the human granulosa cell line COV434.
Pastuschek J; Poetzsch J; Morales-Prieto DM; Schleußner E; Markert UR; Georgiev G
J Reprod Immunol; 2015 Apr; 108():48-55. PubMed ID: 25817464
[TBL] [Abstract][Full Text] [Related]
11. A standardized herbal combination of Astragalus membranaceus and Paeonia japonica, protects against muscle atrophy in a C26 colon cancer cachexia mouse model.
Lee SB; Lee JS; Moon SO; Lee HD; Yoon YS; Son CG
J Ethnopharmacol; 2021 Mar; 267():113470. PubMed ID: 33068652
[TBL] [Abstract][Full Text] [Related]
12. The AB loop and D-helix in binding site III of human Oncostatin M (OSM) are required for OSM receptor activation.
Adrian-Segarra JM; Schindler N; Gajawada P; Lörchner H; Braun T; Pöling J
J Biol Chem; 2018 May; 293(18):7017-7029. PubMed ID: 29511087
[TBL] [Abstract][Full Text] [Related]
13. JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia.
Bonetto A; Aydogdu T; Jin X; Zhang Z; Zhan R; Puzis L; Koniaris LG; Zimmers TA
Am J Physiol Endocrinol Metab; 2012 Aug; 303(3):E410-21. PubMed ID: 22669242
[TBL] [Abstract][Full Text] [Related]
14. Oncostatin M induces C2C12 myotube atrophy by modulating muscle differentiation and degradation.
Miki Y; Morioka T; Shioi A; Fujimoto K; Sakura T; Uedono H; Kakutani Y; Ochi A; Mori K; Shoji T; Emoto M; Inaba M
Biochem Biophys Res Commun; 2019 Aug; 516(3):951-956. PubMed ID: 31272716
[TBL] [Abstract][Full Text] [Related]
15. Exosomal IL-8 derived from Lung Cancer and Colon Cancer cells induced adipocyte atrophy via NF-κB signaling pathway.
Xiong H; Ye J; Xie K; Hu W; Xu N; Yang H
Lipids Health Dis; 2022 Dec; 21(1):147. PubMed ID: 36581870
[TBL] [Abstract][Full Text] [Related]
16. Murine Oncostatin M Acts via Leukemia Inhibitory Factor Receptor to Phosphorylate Signal Transducer and Activator of Transcription 3 (STAT3) but Not STAT1, an Effect That Protects Bone Mass.
Walker EC; Johnson RW; Hu Y; Brennan HJ; Poulton IJ; Zhang JG; Jenkins BJ; Smyth GK; Nicola NA; Sims NA
J Biol Chem; 2016 Oct; 291(41):21703-21716. PubMed ID: 27539849
[TBL] [Abstract][Full Text] [Related]
17. Oncostatin M-induced blood-brain barrier impairment is due to prolonged activation of STAT3 signaling in vitro.
Takata F; Dohgu S; Matsumoto J; Machida T; Sakaguchi S; Kimura I; Yamauchi A; Kataoka Y
J Cell Biochem; 2018 Nov; 119(11):9055-9063. PubMed ID: 30076740
[TBL] [Abstract][Full Text] [Related]
18. Sepsis induces interleukin 6, gp130/JAK2/STAT3, and muscle wasting.
Zanders L; Kny M; Hahn A; Schmidt S; Wundersitz S; Todiras M; Lahmann I; Bandyopadhyay A; Wollersheim T; Kaderali L; Luft FC; Birchmeier C; Weber-Carstens S; Fielitz J
J Cachexia Sarcopenia Muscle; 2022 Feb; 13(1):713-727. PubMed ID: 34821076
[TBL] [Abstract][Full Text] [Related]
19. Anti-oncostatin M antibody inhibits the pro-malignant effects of oncostatin M receptor overexpression in squamous cell carcinoma.
Kucia-Tran JA; Tulkki V; Scarpini CG; Smith S; Wallberg M; Paez-Ribes M; Araujo AM; Botthoff J; Feeney M; Hughes K; Caffarel MM; Coleman N
J Pathol; 2018 Mar; 244(3):283-295. PubMed ID: 29205362
[TBL] [Abstract][Full Text] [Related]
20. STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia.
Bonetto A; Aydogdu T; Kunzevitzky N; Guttridge DC; Khuri S; Koniaris LG; Zimmers TA
PLoS One; 2011; 6(7):e22538. PubMed ID: 21799891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
